Pomerantz LLP is investigating claims on behalf of investors of Aurora Cannabis Inc. (“Aurora Cannabis” or the “Company”) (NASDAQ: ACB). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.comor 646-581-9980, ext.7980. https://mma.prnewswire.com/media/2287619/Pomerantz_V3_Logo.jpg The investigation concerns whether Aurora Cannabis and certain of its officers and/or directors have engaged in securities fraud or other unlawful business […]

Pomerantz LLP is investigating claims on behalf of investors of KBR, Inc. (“KBR” or the “Company”) (NYSE: KBR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.comor 646-581-9980, ext.7980. https://mma.prnewswire.com/media/2287619/Pomerantz_V3_Logo.jpg The investigation concerns whether KBR and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here

Pomerantz LLP is investigating claims on behalf of investors of Lineage, Inc. (“Lineage” or the “Company”) (NASDAQ: LINE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.comor 646-581-9980, ext.7980. https://mma.prnewswire.com/media/2287619/Pomerantz_V3_Logo.jpg The investigation concerns whetherLineage and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for

Pomerantz LLP is investigating claims on behalf of investors ofDesigner Brands Inc.(“Designer Brands” or the “Company”)(NYSE: DBI).Such investors are advised to contact Danielle Peyton atnewaction@pomlaw.comor 646-581-9980, ext.7980. https://mma.prnewswire.com/media/2287619/Pomerantz_V3_Logo.jpg The investigation concerns whether Designer Brands and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information

Pomerantz LLP is investigating claims on behalf of investors ofDyne Therapeutics, Inc.(“Dyne” or the “Company”)(NASDAQ: DYN).Such investors are advised to contact Danielle Peyton atnewaction@pomlaw.comor 646-581-9980, ext.7980. https://mma.prnewswire.com/media/2287619/Pomerantz_V3_Logo.jpg The investigation concerns whetherDyne and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the

Pomerantz LLP is investigating claims on behalf of investors ofCapricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.comor 646-581-9980, ext.7980. https://mma.prnewswire.com/media/2287619/Pomerantz_V3_Logo.jpg The investigation concerns whether Capricor and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here

Pomerantz LLP is investigating claims on behalf of investors of Groupon, Inc. (“Groupon” or the “Company”) (NASDAQ: GRPN).Such investors are advised to contact Danielle Peyton at newaction@pomlaw.comor 646-581-9980, ext.7980. https://mma.prnewswire.com/media/2287619/Pomerantz_V3_Logo.jpg The investigation concerns whether Groupon and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for

Pomerantz LLP is investigating claims on behalf of investors of United Natural Foods, Inc. (“United Natural” or the “Company”) (NYSE: UNFI). Such investors are advised to contact Danielle Peyton atnewaction@pomlaw.comor 646-581-9980, ext.7980. https://mma.prnewswire.com/media/2287619/Pomerantz_V3_Logo.jpg The investigation concerns whether United Natural and certain of its officers and/or directors have engaged in securities fraud or other unlawful business

Pomerantz LLP announces that a class action lawsuit has been filed against Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”) (NYSE: HIMS). Such investors are advised to contact Danielle Peyton atnewaction@pomlaw.comor 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and

Pomerantz LLP is investigating claims on behalf of investors ofSarepta Therapeutics, Inc.(“Sarepta” or the “Company”)(NASDAQ: SRPT).Such investors are advised to contact Danielle Peyton atnewaction@pomlaw.comor 646-581-9980, ext.7980. https://mma.prnewswire.com/media/2287619/Pomerantz_V3_Logo.jpg The investigation concerns whetherSarepta and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the